Comment from Kati Malicoate

I appreciate the opportunity to comment on the Food and Drug Administration’s ongoing work to strengthen the safety, transparency, and oversight of compounded drug products, as outlined in the October 27, 2015 Federal Register notice announcing the establishment of a public docket for bulk drug substances under Section 503B of the Food, Drug, and Cosmetic Act. This action marks an important step toward a more accountable compounding landscape — one that centers patient safety while preserving access to clinically necessary, individualized care. As a graduate student focusing on health policy, I spend a significant amount of time studying the systems and regulations that shape how medications reach patients — and, more importantly, where those systems succeed or fall short. The issues raised in this notice speak directly to what I’ve learned: medication safety and drug quality don’t impact everyone equally. When oversight gaps occur, the communities already facing barriers to care are often the ones most harmed. This docket appropriately threads that needle by grounding eligibility for the 503B bulks list in a clear demonstration of clinical need. The FDA’s expectation that nominators provide specific, evidence-based justification — including details about target populations, incompatibilities with approved products, relevant safety data, and reasons bulk compounding is necessary — is not bureaucratic red tape. It’s essential. When compounded drugs are made from bulk substances without strong justification, we risk drifting away from patient-specific clinical care and toward a shadow market of unapproved formulations. That serves neither public health nor the integrity of the health-care system. I strongly support FDA’s decision to reject “boilerplate” rationales and general statements about convenience, cost, or preference as valid bases for inclusion. Those factors, while important in broader access-to-care conversations, do not constitute clinical need in the regulatory sense. The Agency is right to insist that nominations be tied to identifiable gaps in FDA-approved treatments — for example, patients with excipient allergies, those requiring alternative dosage forms, or populations whose needs aren’t met by available strengths or routes of administration. Additionally, the transparency built into this process is a major strength. A publicly accessible docket, the ability for stakeholders to comment on individual substances, and clear instructions for submitting confidential information all help ensure a fair, inclusive, and rigorous review. The decision to require renomination of previously unsupported substances also protects FDA from being pressured into decisions based on incomplete data. Further, I think it’s important to name how this framework can actually move us toward better health equity. When “clinical need” is defined carefully and not treated as a box-checking exercise, it creates space for the people who usually get overlooked — patients with disabilities who need alternative formulations, kids who don’t fit standard dosing, or anyone who depends on a niche version of a medication that simply doesn’t exist on the commercial market. Holding nominations to real safety and efficacy standards matters too, because the harm from weak oversight has never fallen evenly; it’s almost always the same communities who end up carrying that risk. I’d urge the FDA to keep communication with clinicians, pharmacists, and health-system leaders front and center as this process moves forward. A lot of prescribers who use compounded medications might not be familiar with how much evidence is actually needed to justify a clinical-need determination. Clear, practical guidance — not just one-time instructions but ongoing outreach — can go a long way toward avoiding confusion, improving the quality of nominations, and building a more rigorous, evidence-based compounding system overall. Stepping back, the general approach outlined in the notice feels like the right balance. It doesn’t shut the door on patients who genuinely need compounded medications, but it also doesn’t allow bulk drug substances to slip through without solid justification. Grounding decisions in documented clinical need, requiring transparent evidence, and inviting public participation creates a stronger, more trustworthy system — one that protects patient safety while still making sure people who truly rely on compounded care aren’t left without options. Thank you for your attention and for the opportunity to comment.